Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
James McCormack a Faculty of
Pharmaceutical Sciences, University of British Columbia, Vancouver,
Canada V6T 1W5, b Department of Primary Care and Population Sciences, Royal Free
and University College Medical School, London N19 3UA
Correspondence to: J
McCormack jmccorma@interchange.ubc.ca
| The first 150 words of the full text of this article appear below. |
Randomised controlled trials are objective, free of bias,
and produce robust conclusions about the benefits and risks of
treatment, and clinicians should be trained to rely on them; so says
the gospel of evidence based practice. In this article we argue, using the United Kingdom prospective diabetes study (UKPDS) as an example, that there is one stage in the conduct of a randomised controlled trial
the interpretation and dissemination of results
that is open to
several biases that can seriously distort the conclusions. By bias, we
mean the epidemiological definition: anything that systematically
distorts the comparisons between groups. We will argue that certain
biases arise when different stakeholders assign their individual values
to the interpretation of the final results of randomised controlled
trials.
| Table Removed (Available Only in the Full Text) |
| |
Marketing the UK prospective diabetes study results |
|---|
Until 1998, type 2 diabetes had been treated for over 25 years with drugs such as the sulphonylureas, insulin, and metformin. Only one well designed, prospective clinical trial had evaluated
Read all Rapid Responses